Eli Lilly Partners with Revive Health to Streamline Direct-to-Employer Obesity Care
Indianapolis, Friday, 6 March 2026.
Eli Lilly selected Revive Health to facilitate direct-to-employer obesity care, joining a strategic initiative of 18 partners designed to bypass pharmacy benefit managers and streamline Zepbound access.
Strategic Partnership Announcement
On Friday, March 6, 2026, Eli Lilly (LLY) formally announced the selection of Revive Health as a key care delivery partner aimed at expanding employer access to obesity care management [1]. This collaboration leverages Revive’s integrated platform, which consolidates physician-led care, behavioral health support, pharmacy services, and digital tools into a single interface for employees [1]. The initiative is designed to address the rising demand among employers for coordinated care programs that do not merely dispense medication but also provide the necessary lifestyle coaching and clinical oversight to ensure sustainable health outcomes [1].
Structural Shift in Benefit Management
Revive Health is one of 18 firms selected to facilitate this direct access, joining a diverse roster that includes Mark Cuban Cost Plus Drug Company, Teladoc Health, Calibrate, and Sesame [2]. The sheer number of partners indicates a significant shift in the market, with industry observers noting that the primary goal of this benefit design is to bypass PBMs entirely for the time being [2]. Through this network, employers can offer manufacturer-priced Zepbound alongside structured obesity care programs that integrate contracting and medication access [2].
Contrasting Regulatory Pressures
The establishment of these authorized, direct channels comes at a time of heightened regulatory scrutiny regarding alternative sources of weight-loss medications. On Tuesday, March 3, 2026, the U.S. Food and Drug Administration (FDA) issued warning letters to 30 telehealth companies for making false or misleading claims regarding compounded versions of popular GLP-1 drugs [3]. The agency cited these firms for marketing compounded products as identical to approved drugs and for obscuring the source of the medications to appear as the original manufacturers [3].